NHP 229

Drug Profile

NHP 229

Alternative Names: NHP-229

Latest Information Update: 31 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator New Haven Pharmaceuticals
  • Class Zinc compounds
  • Mechanism of Action Antacids
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Gastro-oesophageal reflux

Most Recent Events

  • 31 Mar 2016 Phase-I clinical trials in Gastro-oesophageal reflux (Adjunctive treatment) in USA (PO)
  • 30 Jan 2014 Preclinical trials in Gastro-oesophageal reflux (adjunctive treatment) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top